Inhibitors selective for HDAC6 in enzymes and cells
✍ Scribed by Praveer K. Gupta; Robert C. Reid; Ligong Liu; Andrew J. Lucke; Steve A. Broomfield; Melanie R. Andrews; Matthew J. Sweet; David P. Fairlie
- Publisher
- Elsevier Science
- Year
- 2010
- Tongue
- English
- Weight
- 412 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0960-894X
No coin nor oath required. For personal study only.
✦ Synopsis
Histone deacetylase inhibitors with anticancer or anti-inflammatory activity bind to Class I or Class I and II HDAC enzymes. Here we compare selectivity of inhibitors of a Class II HDAC enzyme (HDAC6) and find one that retains high selectivity in macrophages.
📜 SIMILAR VOLUMES
We previously reported silencing of the TGF-b type II receptor gene (TGFbRII), involving histone deacetylation, instead of DNA methylation (DNA-Me). Because different histone modifications may play crucial roles in the epigenetic alterations, we further studied links with silencing of the TGFbRII ge
p-Iodobenzenesulphonamide (pIBS), a potent red cell carbonic anhydrase inhibitor, was used as a carrier for radioiodine in the enzyme-inhibitor approach to cell-specific blood labelling. Radioactivity distribution was monitored in rats and man following i.v. administration of the radiolabelled carri
Red cell carbonic anhydrase is identified as an ideal target in an enzyme-inhibitor approach to radiolabel localisation. Current problems in blood pool labelling could be overcome by using selective sulphonamide inhibitors as carriers. p-Iodobenzenesulphonamide (pIBS) was selected as the choice reag